The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated with natalizumab, a monoclonal antibody against α 4 integrins, was reclassified as JC virus–related ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...

Please provide your email address to receive an email when new articles are posted on . Use of a genetic risk test for patients considering immunosuppressive therapies associated with development of ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

A new study found dozens of FDA approved drugs can increase the risk of developing progressive multifocal leukoencephalopathy, a rare and often fatal brain infection, by an average of eight times. The ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...

Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). Background: Rituximab is an anti-CD20 monoclonal antibody which has ...

New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of ...

Progressive multifocal leukoencephalopathy (PML) occurring with ocrelizumab (Ocrevus) monotherapy developed in a 78-year-old man with progressive multiple sclerosis (MS), the first such case known, ...

Kamble et al. 1 recently provided a review of cases of central nervous system graft-versus-host disease (CNS GVHD). The authors conclude that ‘when relapse of a CNS neoplastic process, opportunistic ...

ROCKVILLE, Md.--(BUSINESS WIRE)--NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the pilot ...